High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia High sensitivity and high negative predictive value (NPV) observed for ruling out the risk of preeclampsia
NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 20, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced positive in vitro data by its joint venture partner NLC Pharma for the Company’s dietary supplement Tollovid™, demonstrating its ability to inhibit the 3CL protease. The 3CL protease is an enzyme that is required for the intracellular replication of coronaviruses. Tollovid received a certificate of free sale from the FDA in August 2020 and is being launched commercially into the US market initially at botanical wellness store The Alchemist’s Kitchen™ in New York City.
NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow’s Chief Executive Officer, and Andrew Boll, Harrow’s Chief Financial Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1 – 3, 2020.
Go here to read the rest:
Harrow Health Announces Participation at the Piper Sandler 32nd Annual Healthcare Conference
CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the nomination of BDTX-1535 as the Company’s development candidate for the treatment of glioblastoma multiforme (GBM), as well as the commencement of Investigational New Drug (IND)-enabling studies.
See the original post here:
Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting
Voorhies has Extensive Business and Industry Experience in Diagnostics & Monitoring
More here:
Aditxt Appoints Anthony Voorhies as Head of Business Development for AditxtScore™
MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
See the original post:
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:
Excerpt from:
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that it will host an expert panel on acromegaly and the results from its recently completed MPOWERED® Phase 3 clinical trial on Monday, November 30, 2020 at 11:00 am Eastern Time.
Read the original:
Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results
RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 32nd Annual Healthcare Conference.
More here:
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference
WOODCLIFF LAKE, NJ, Nov. 20, 2020 (GLOBE NEWSWIRE) -- NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it has signed waiver agreements with certain of its existing institutional investors.
Follow this link:
Timber Pharmaceuticals Signs Waiver Agreement with Warrant Holders